论文部分内容阅读
目的 探讨神经生长因子联合前列地尔对2型糖尿病痛性神经病变(PDN)的治疗效果.方法 以2015年1月—2017年3月156例2型糖尿病PDN患者为研究对象,随机分为观察组和对照组各78例.两组均予以饮食、运动干预,以及降糖、降脂等常规治疗.对照组在常规治疗基础上加用注射用鼠神经生长因子,9,000 AU/次,1次/d.观察组在对照组基础上加用前列地尔注射液,20μg/次,1次/d.疗程均为1周.治疗后对两组临床疗效进行判断,比较治疗前后正中神经和腓总神经传导速度,足部压力觉异常点数,MNSI症状问卷和足部检查评分.结果 观察组临床疗效显著优于对照组(P<0.05).与治疗前比较,两组治疗后正中神经和腓总神经运动神经传导速度(MCV)和感觉神经传导速度(SCV)均提高(P<0.05),且观察组高于对照组(P<0.05);两组治疗后足部压力觉异常点数和MNSI评分均下降(P<0.05),且观察组低于对照组(P<0.05).结论 神经生长因子联合前列地尔治疗2型糖尿病PDN的临床效果满意,可明显改善患者神经传导速度,减少足部压力觉异常点数和MNSI评分.“,”Objective To investigate the clinical efficacy of nerve growth factor combined with alprostadil on painful diabetic neuropathy (PDN). Methods A total of 156 patients with PDN treated in our hospital from January 2015 to March 2017 were selected as research objects. All of the patients were randomly assigned into observation group and control group. All of the patients were treated with intervention of diet and exercise, and decreasing of sugar and lipid. Patients in the control group were treated with nerve growth factor (9,000 AU/time, 1 time/d) on the basis of conventional therapy, while patients in the observation group were treated with alprostadil (20μg/time, 1 time/d) on the basis of the control group. The course of treatment was 1 week. The clinical efficacy of the two groups was evaluated after treatment. The median nerve and peroneal nerve conduction velocity, the number of abnormal foot pressure sensation, the MNSI symptom questionnaire and the foot test score were compared before and after treatment. Results The clinical efficacy of the observation group was significantly better than that of the control group (P<0.05). Compared with before treatment, the MCV and SCV of median and common peroneal nerve in the two groups were improved (P<0.05), and the observation group was higher than that of the control group (P<0.05). Compared with before treatment, the number of abnormal foot pressure sensation and the MNSI score were decreased (P<0.05), and the observation group was lower than that of the control group (P<0.05). Conclusion The clinical efficacy of nerve growth factor combined with alprostadil in treatment of PDN is satisfactory. It can significantly improve the nerve conduction velocity, reduce the abnormal number of foot pressure sensation and MNSI score.